A Comprehensive MS educational program videotaped on Nov 9th from Atlanta, Ga
THIS video was a Live presentation. we archived it so You can have access to what hundreds viewed in person…
More Neurologists Now Mention Once-Daily Dosing As Aubagio’s Biggest Advantage
PRESS RELEASE Nov. 25, 2013, Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzyme’s Aubagio to Their Multiple Sclerosis Patients at…
Stuart Schlossman
Biogen Idec Gets European Protection For MS Drug Tecfidera – Quick Facts
November 22, 2013 (RTTNews.com) – Biogen Idec ( BIIB ) said Friday that the Committee for Medicinal Products for Human Use or…
Stuart Schlossman
U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction
Nevertheless, Injectables Remain First-Line Mainstays Among Newly Diagnosed Patients, According to a New Report from Decision Resources By Decision Resources Published:…
Stuart Schlossman
New data show Novartis’ Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients
October 04, 2013 New four-year data showed that continued Gilenya treatment reduced brain volume loss by one third when compared…
Stuart Schlossman
Emerging MS Treatment Therapies, MS Relapse, Adherence, Compliance, Symptom Management, Energy Conservation and Adaptive Devices – Atlanta 2013
MS Views and News – Atlanta 2013 Click here to view (our video) http://www.youtube.com/watch?v=r8E7iVxe07M This program on November 9, 2013,…
Stuart Schlossman
Learn More of the Oral MS Medications
Click to learn about the current (3) Oral MS medications Gilenya : http://www.gilenya.com/index.jsp Aubagio : https://www.aubagio.com/ Tecfidera: http://www.tecfidera.com/ …….. To comment –…
Stuart Schlossman
Patient Stories about their use with Tecfidera
November 1, 2013 Stu, I started Tecfidera on May 18, 2013. I was a little nervous, but was excited to…
Stuart Schlossman
New TECFIDERA Data Show Sustained Efficacy and Long-Term Safety in MS Patients
New TECFIDERA® (Dimethyl Fumarate) Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients Interim…
Stuart Schlossman
BG-12: Sustained Efficacy, Safety Out to 4 Years in MS
COPENHAGEN, Denmark — Latest results from the clinical trial program with BG-12 (dimethyl fumarate; Tecfidera, Biogen Idec) suggest sustained clinical efficacy…
Stuart Schlossman
